347 related articles for article (PubMed ID: 37198444)
1. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
2. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
Tezuka Y; Turcu AF
Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
[TBL] [Abstract][Full Text] [Related]
3. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
6. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
7. Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade.
Pintus G; Seccia TM; Amar L; Azizi M; Riester A; Reincke M; Widimský J; Naruse M; Kocjan T; Negro A; Kline G; Tanabe A; Satoh F; Rump LC; Vonend O; Fuller PJ; Yang J; Chee NYN; Magill SB; Shafigullina Z; Quinkler M; Oliveras A; Lee BC; Chang CC; Wu VC; Krátká Z; Battistel M; Bagordo D; Caroccia B; Ceolotto G; Rossitto G; Rossi GP
Hypertension; 2024 Jun; 81(6):1391-1399. PubMed ID: 38525605
[TBL] [Abstract][Full Text] [Related]
8. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
[TBL] [Abstract][Full Text] [Related]
9. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
[TBL] [Abstract][Full Text] [Related]
10. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Tezuka Y; Turcu AF
Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
[TBL] [Abstract][Full Text] [Related]
11. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism.
Weiner ID
Semin Nephrol; 2013 May; 33(3):265-76. PubMed ID: 23953804
[TBL] [Abstract][Full Text] [Related]
12. Primary Aldosteronism: Present and Future.
Funder JW
Vitam Horm; 2019; 109():285-302. PubMed ID: 30678860
[TBL] [Abstract][Full Text] [Related]
13. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
Rakugi H; Yamakawa S; Sugimoto K
Hypertens Res; 2021 Apr; 44(4):371-385. PubMed ID: 33214722
[TBL] [Abstract][Full Text] [Related]
14. Personalized Treatment of Patients With Primary Aldosteronism.
Obeid H; Chen Cardenas SM; Khairi S; Turcu AF
Endocr Pract; 2023 Jun; 29(6):484-490. PubMed ID: 36273684
[TBL] [Abstract][Full Text] [Related]
15. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
Gregg LP; Navaneethan SD
Nephrol Dial Transplant; 2023 May; 38(6):1355-1365. PubMed ID: 36264349
[TBL] [Abstract][Full Text] [Related]
16. Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
Fountoulakis S; Papanastasiou L; Voulgaris N; Kounadi T; Markou A; Chrousos GP; Piaditis G
Hormones (Athens); 2020 Jun; 19(2):223-232. PubMed ID: 31863347
[TBL] [Abstract][Full Text] [Related]
17. Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension.
Mansur A; Vaidya A; Turchin A
Am J Hypertens; 2023 Jul; 36(8):455-461. PubMed ID: 37013957
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of primary aldosteronism.
Vilela LAP; Almeida MQ
Arch Endocrinol Metab; 2017; 61(3):305-312. PubMed ID: 28699986
[TBL] [Abstract][Full Text] [Related]
19. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
[TBL] [Abstract][Full Text] [Related]
20. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]